Published in Curr HIV Res on January 01, 2011
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother (2012) 0.89
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. PLoS One (2012) 0.81
Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients. Clin Med Rev Ther (2011) 0.80
Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics. Neurotox Res (2016) 0.79
Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. Clin Infect Dis (2017) 0.75
Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Res Ther (2016) 0.75
Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND. Brain Sci (2017) 0.75
Psychiatric Symptoms in Patients Receiving Dolutegravir. J Acquir Immune Defic Syndr (2016) 0.75
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 7.08
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Immune restoration disease after antiretroviral therapy. AIDS (2004) 4.54
Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis (2006) 2.52
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis (2005) 2.36
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.83
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis (2005) 1.70
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS (2003) 1.43
Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther (1999) 1.37
Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis (2006) 1.35
Depression in patients with HIV infection. Am J Health Syst Pharm (2000) 1.30
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr (2010) 1.17
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med (2003) 1.15
Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother (2008) 1.14
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr (2005) 1.13
Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med (2006) 1.07
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother (2005) 1.07
Abacavir: a review of its clinical potential in patients with HIV infection. Drugs (2000) 1.00
Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials (2005) 0.92
Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS (2008) 0.87
Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS (2002) 0.84
Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep (2005) 0.83
Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr (2001) 0.82
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. Antivir Ther (2004) 0.81
Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review. Top HIV Med (2006) 0.77
Immune restoration disease in HIV patients: aberrant immune responses after antiretroviral therapy. J HIV Ther (2002) 0.76
Sub1A is an ethylene-response-factor-like gene that confers submergence tolerance to rice. Nature (2006) 6.68
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet (2002) 2.41
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Drosophila liprin-alpha and the receptor phosphatase Dlar control synapse morphogenesis. Neuron (2002) 2.33
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat (2014) 2.10
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One (2010) 1.93
Highwire regulates presynaptic BMP signaling essential for synaptic growth. Neuron (2004) 1.91
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.83
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
Active zone localization of presynaptic calcium channels encoded by the cacophony locus of Drosophila. J Neurosci (2004) 1.55
Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2012) 1.53
TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest (2012) 1.52
Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine (2011) 1.51
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One (2009) 1.48
Towards establishment of a rice stress response interactome. PLoS Genet (2011) 1.47
Protein-protein interactions of tandem affinity purification-tagged protein kinases in rice. Plant J (2006) 1.42
Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun (2006) 1.41
Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev (2009) 1.37
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses (2009) 1.36
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother (2012) 1.36
A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev (2008) 1.32
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine (2003) 1.29
Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics (2010) 1.29
Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res (2011) 1.28
Regulation of heterochromatin assembly on unpaired chromosomes during Caenorhabditis elegans meiosis by components of a small RNA-mediated pathway. PLoS Genet (2009) 1.28
Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res (2010) 1.27
Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol (2012) 1.22
Patterns of diagnoses in hospital admissions in a multistate cohort of HIV-positive adults in 2001. Med Care (2005) 1.22
Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res (2013) 1.21
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr (2010) 1.17
Lack of plakophilin 1 increases keratinocyte migration and reduces desmosome stability. J Cell Sci (2003) 1.16
Effect of extracellular ph on matrix synthesis by chondrocytes in 3D agarose gel. Biotechnol Prog (2007) 1.16
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos (2010) 1.16
Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol (2002) 1.15
MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer (2014) 1.14
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol (2009) 1.13
Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. Carcinogenesis (2013) 1.13
Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. J Clin Endocrinol Metab (2008) 1.10
miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma. Carcinogenesis (2013) 1.10
Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomarkers Prev (2010) 1.10
Temperature sensitivity of soil organic carbon mineralization along an elevation gradient in the Wuyi Mountains, China. PLoS One (2013) 1.09
Economic evaluation of measles catch-up and follow-up campaigns in Afghanistan in 2002 and 2003. Disasters (2006) 1.08
Retrotransposition of limited deletion type of intracisternal A-particle elements in the myeloid leukemia Clls of C3H/He mice. J Radiat Res (2004) 1.08
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS One (2013) 1.07
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci (2011) 1.06
Accelerated rubella control and congenital rubella syndrome prevention strengthen measles eradication: the Costa Rican experience. J Infect Dis (2003) 1.05
Effects of clinical characteristics on successful open access scheduling. Health Care Manag Sci (2007) 1.04
Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One (2011) 1.03
miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncol Lett (2013) 1.03
Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin (2011) 1.03
Epidemiological profile of rotavirus infection in the Republic of Korea: results from prospective surveillance in the Jeongeub District, 1 July 2002 through 30 June 2004. J Infect Dis (2005) 1.02
CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis (2007) 1.02
Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One (2012) 1.01
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem (2009) 1.01
RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells. J Cell Mol Med (2014) 1.00
Human-like immune responses in CD46 transgenic mice. J Immunol (2005) 1.00
Cryopreservation of human bone marrow-derived mesenchymal stem cells with reduced dimethylsulfoxide and well-defined freezing solutions. Biotechnol Prog (2010) 0.99
Influence of ovariectomy and 17beta-estradiol treatment on insulin sensitivity, lipid metabolism and post-ischemic cardiac function. Int J Cardiol (2004) 0.99
Helicobacter pylori CagA inhibits the expression of Runx3 via Src/MEK/ERK and p38 MAPK pathways in gastric epithelial cell. J Cell Biochem (2012) 0.99
Hospital-based study of the economic burden associated with rotavirus diarrhea in Hong Kong. J Infect Dis (2005) 0.98
The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol (2011) 0.98
Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases. Hum Pathol (2011) 0.98
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses (2013) 0.97
JMJD2B promotes epithelial-mesenchymal transition by cooperating with β-catenin and enhances gastric cancer metastasis. Clin Cancer Res (2013) 0.97
Immunosensors for detection of pesticide residues. Biosens Bioelectron (2008) 0.97
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis (2013) 0.97
Urinary estrogen metabolites and their ratio among Asian American women. Cancer Epidemiol Biomarkers Prev (2005) 0.97
Identification and functional analysis of light-responsive unique genes and gene family members in rice. PLoS Genet (2008) 0.96
Combination of curcumin and green tea catechins prevents dimethylhydrazine-induced colon carcinogenesis. Food Chem Toxicol (2009) 0.96
Estimates of rotavirus disease burden in Hong Kong: hospital-based surveillance. J Infect Dis (2005) 0.96
Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma. J Invest Dermatol (2002) 0.95
Comparison of estrogens and estrogen metabolites in human breast tissue and urine. Reprod Biol Endocrinol (2010) 0.94
Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med (2012) 0.94